Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acromegaly. Recognition and treatment

C A Jaffe1, A L Barkan

  • 1Division of Endocrinology and Metabolism, Taubman Center, University of Michigan Medical Center, Ann Arbor.

Drugs
|March 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of pulsatile growth hormone (GH) secretion in the regulation of lipolysis in fasting humans.

Clinical diabetes and endocrinology·2022
Same author

Acromegalic arthropathy.

Pituitary·2002
Same author

Pergolide as primary therapy for macroprolactinomas.

Pituitary·2002
Same author

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.

Lancet (London, England)·2001
Same author

Semiquantification of hypothalamic GH-releasing hormone output in women: evidence for sexual dimorphism in the mechanism of the somatopause.

The Journal of clinical endocrinology and metabolism·2001
Same author

Regulation of GH secretion in acromegaly: reproducibility of daily GH profiles and attenuated negative feedback by IGF-I.

The Journal of clinical endocrinology and metabolism·2001

Acromegaly, caused by excess growth hormone (GH), leads to serious health issues. Early diagnosis through clinical vigilance and elevated insulin-like growth factor I (IGF-I) is crucial for effective treatment.

Area of Science:

  • Endocrinology
  • Oncology

Background:

  • Acromegaly results from excess growth hormone (GH) secretion, typically from pituitary adenomas.
  • Delayed diagnosis leads to significant cardiac, pulmonary, and musculoskeletal morbidity and mortality.
  • Pituitary tumor mass can cause local complications.

Purpose of the Study:

  • To outline the diagnostic and therapeutic strategies for acromegaly.
  • To emphasize the importance of clinical vigilance and biochemical testing in diagnosis.
  • To review current treatment options for GH-secreting pituitary tumors.

Main Methods:

  • Clinical assessment and vigilance.
  • Biochemical testing, primarily measuring plasma insulin-like growth factor I (IGF-I).
  • Imaging studies including MRI and CT scans of the pituitary gland and hypothalamus.

Related Experiment Videos

  • Evaluation of therapeutic interventions: surgical resection, radiation, and medical therapies (bromocriptine, octreotide).

    • Main Results:

    • Elevated IGF-I is the key diagnostic marker for acromegaly.
    • Surgical tumor resection is the primary treatment.
    • Further treatment with radiation or medication is necessary if GH secretion remains high, assessed by normalized IGF-I.
    • Octreotide demonstrates higher efficacy than bromocriptine in normalizing GH and reducing tumor size.

    Conclusions:

    • Early diagnosis of acromegaly through clinical suspicion and IGF-I measurement is vital.
    • Multimodal treatment, starting with surgery, is essential for managing GH hypersecretion and tumor mass.
    • Octreotide shows promise as a more effective medical therapy for acromegaly compared to bromocriptine.